Fresenius SE
 |
|
| Kommanditgesellschaft auf Aktien with Societas Europaea as partner with unlimited liability | |
| Traded as |
|
| Industry | Health care |
| Founded | 1912 |
| Headquarters | Bad Homburg, Germany |
|
Key people
|
Stephan Sturm (CEO and chairman of the management board), Gerd Krick (Chairman of the supervisory board) |
| Products | Kidney dialysis, infusion pumps, drugs, hospitals, medical care |
| Revenue | €27.995 billion (2015) |
| €4.001 billion (2015) | |
| Profit | €1.436 billion (2015) |
| Total assets | €43.170 billion (end 2015) |
| Total equity | €18.131 billion (end 2015) |
|
Number of employees
|
223,704 (March 2016) |
| Website | www.fresenius.com |
Fresenius SE & Co. KGaA is a German health care company based in Bad Homburg. The Fresenius Group provides products and services for dialysis, hospitals as well as inpatient and outpatient medical care. In addition, the company focuses on hospital management as well as on engineering and services for medical centers and other health care facilities. The company is a component of the Euro Stoxx 50 .
Fresenius consists of four business segments, Fresenius Medical Care (a publicly traded company of which Fresenius owns 30.8%), Fresenius Helios, Fresenius Kabi and Fresenius Vamed. With activities in about 100 countries, it has more than 200,000 employees.
Another arm of Fresenius Kabi is Fresenius Kabi Oncology Plc. It produces generics of intravenous oncology products such as Paclitaxel, Irinotecan, Oxaliplatin, Gemcitabine, Cytarabine, Carboplatin, Topotecan, Docetaxel and Epirubicin.
Fresenius owns the Helios Kliniken, which has more than 100 hospitals and more than 30,000 beds, treating over 4 million patients annually. The hospital operator is the biggest provider of inpatient and outpatient care in Germany.
The North American branch of Fresenius Medical Care is headquartered in Waltham, Massachusetts.
The company was founded by Eduard Fresenius (1874–1946) in 1912.
In 1946, Fresenius left the company to Else Kröner, his foster-daughter and protege, who was still in pharmacy school at the time. Else Kröner rescued the company from significant debts by laying off the majority of staff and restructuring the business. By Kröner's death in 1988, the company was an international leader. Kröner's will endowed the Else Kröner-Fresenius-Foundation, which funds medical research.
On July 16, 2007, the company completed its conversion from an Aktiengesellschaft (AG - German public limited company) to a Societas Europaea, the European Union-wide equivalent. The company changed its legal status once again on January 28, 2011, becoming a Kommanditgesellschaft auf Aktien (KGaA - German partnership limited by shares) with a Societas Europaea as a partner with unlimited liability (SE & Co. KGaA).
...
Wikipedia